Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (91-100 of 155) with videos related to

Pageof 16
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 19, 2008
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trialPhilip M Poortmans, Laurence Collette, Jean-Claude Horiot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trialHarry Bartelink, Jean-Claude Horiot, Philip M Poortmans, et al.
European Urology|September 1, 2009
Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancerJoost L Boormans, Karin G Hermans, Angelique C J Ziel-van der Made, et al.
JAMA Oncology|December 13, 2019
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical TrialsSafae Terrisse, Eleni Karamouza, Chris C Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20)Sophie D Fosså, Ronald de Wit, J Trevor Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 2, 2018
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042)Damien C Weber, Carmen Ares, Salvador Villa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2014
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunitiesMarieke van Leeuwen, Fabio Efficace, Sophie D Fosså, et al.
Pageof 16

Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 19, 2008
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trialPhilip M Poortmans, Laurence Collette, Jean-Claude Horiot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trialHarry Bartelink, Jean-Claude Horiot, Philip M Poortmans, et al.
European Urology|September 1, 2009
Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancerJoost L Boormans, Karin G Hermans, Angelique C J Ziel-van der Made, et al.
JAMA Oncology|December 13, 2019
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical TrialsSafae Terrisse, Eleni Karamouza, Chris C Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20)Sophie D Fosså, Ronald de Wit, J Trevor Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 2, 2018
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042)Damien C Weber, Carmen Ares, Salvador Villa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2014
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunitiesMarieke van Leeuwen, Fabio Efficace, Sophie D Fosså, et al.
Pageof 16